Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib mesylate in advanced low grade solid tumors expressing imatinib targets
2008-000688-41Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in Non-hematologic malignancy, malignant solitary fibrous tumor (SFT) and Neoplasm, sponsored by European Institute of Oncology. Primary endpoint: overall response rate. Started Apr 2008; status: completed.
02
Drugs
03
Conditions
Non-hematologic malignancymalignant solitary fibrous tumor (SFT)Neoplasm
Beyond the preview
Go deeper on 2008-000688-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000688-41.